#USA #Houston #ARPA-H #EverGlade #Kate Teffer

EverGlade Expands Its Federal Health Research Expertise

In an important development for the public health sector, EverGlade, a prominent advisory firm specializing in life sciences and technology, has announced that Dr. Kate Teffer will join the organization as a Senior Technical Strategist. With a robust background in federal biomedical research, Dr. Teffer's appointment marks a significant step towards enhancing the firm's capabilities in supporting innovative health initiatives.

Dr. Teffer brings over ten years of invaluable experience from her tenure with various federal biomedical research organizations, most notably the Advanced Research Projects Agency for Health (ARPA-H), where she played a pivotal role in shaping and evaluating research concepts. Her experience extends to collaborations with the National Institutes of Health (NIH), the Department of Defense (DoD), and the Department of Veterans Affairs (VA), addressing critical areas including neuroscience, infectious diseases, precision medicine, and advanced diagnostics.

Before her new position at EverGlade, Dr. Teffer was an integral part of ARPA-H's Health Science Futures Mission Office. There, she not only served as a scientific advisor but also contributed significantly as a science writer. Her efforts included co-authoring key documents that outlined the agency’s vision and mission. Furthermore, she led the scientific review documentation for some of the earliest funded projects, providing her with a deep understanding of what it takes for innovative ideas to translate into actionable research initiatives.

Reflecting on her journey, Dr. Teffer remarked, "ARPA-H was founded on the belief that the most persistent health challenges facing Americans require urgent and ambitious solutions akin to those in national security. My time at the agency has equipped me with the insights necessary to navigate the complexities of transforming bold scientific ideas into funded projects."

Her comments also underline her enthusiasm for joining EverGlade, a firm she describes as distinguishable from traditional consulting outfits. She emphasized, "They truly understand the interplay between science and the federal landscape, allowing me to effectively assist clients in shaping complex technical concepts into clear, compelling future programs."

Prior to her role at ARPA-H, Dr. Teffer dedicated a decade at Booz Allen Hamilton, where she contributed to numerous NIH, DoD, and VA research programs. Her leadership in evidence synthesis and portfolio analysis, particularly in pandemic preparedness and military health research, has been pivotal in shaping strategic planning across various health initiatives.

Giacomo Apadula, CEO of EverGlade, expressed confidence in Dr. Teffer's ability to bring unique insights into how federal health agencies evaluate scientific concepts, thereby defining success in program implementation. He stated, "Kate's firsthand knowledge, combined with her technical expertise, will provide our clients with exceptional perspectives that are crucial for developing high-impact, fundable research projects."

EverGlade's commitment to facilitating the entire funding lifecycle—from crafting technical strategies and proposals to negotiating and executing post-award tasks—positions the firm as a key player in the health innovation sector. Having secured over $3 billion in funding while actively managing 50 programs, the firm is poised to support a wide range of high-risk, high-impact projects.

As Dr. Teffer embarks on this new chapter at EverGlade, it is clear that her extensive experience and strategic insight will be instrumental in further advancing the firm’s role in federal health research and innovation. With her joining the team, clients can expect a renewed emphasis on transforming complex scientific challenges into viable funding opportunities, ultimately propelling forward significant advancements in public health.

For more information about EverGlade and its initiatives, you can visit their official website.